Brind.

Foundation Fighting Blindness and Institut de recherche pour le développement are funding Opus Genetics' work on gene therapies targeting pathogenic variants in the Mer gene.

1 report, 0 independent Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Foundation Fighting Blindness and Institut de recherche pour le développement are funding Opus Genetics' work on gene therapies targeting pathogenic variants in the Mer gene.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet